CL2013000085A1 - Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras. - Google Patents
Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.Info
- Publication number
- CL2013000085A1 CL2013000085A1 CL2013000085A CL2013000085A CL2013000085A1 CL 2013000085 A1 CL2013000085 A1 CL 2013000085A1 CL 2013000085 A CL2013000085 A CL 2013000085A CL 2013000085 A CL2013000085 A CL 2013000085A CL 2013000085 A1 CL2013000085 A1 CL 2013000085A1
- Authority
- CL
- Chile
- Prior art keywords
- chlorophenoxy
- methylpropyl
- pyrrolidine
- obesity
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y ácido clorhídrico en una relación molar 1:1; composición farmacéutica; proceso de preparación; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36277310P | 2010-07-09 | 2010-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013000085A1 true CL2013000085A1 (es) | 2013-03-15 |
Family
ID=44510052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013000085A CL2013000085A1 (es) | 2010-07-09 | 2013-01-09 | Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras. |
Country Status (19)
Country | Link |
---|---|
US (4) | US8163794B2 (es) |
EP (1) | EP2590941A1 (es) |
JP (2) | JP5823512B2 (es) |
KR (1) | KR20130041916A (es) |
CN (1) | CN103038211B (es) |
AR (1) | AR083512A1 (es) |
AU (1) | AU2011276416B2 (es) |
BR (1) | BR112013000602A2 (es) |
CA (1) | CA2803090A1 (es) |
CL (1) | CL2013000085A1 (es) |
CO (1) | CO6680604A2 (es) |
IL (1) | IL223584A0 (es) |
MX (1) | MX2013000334A (es) |
NZ (1) | NZ605490A (es) |
RU (1) | RU2013105479A (es) |
SG (1) | SG186789A1 (es) |
TW (1) | TW201206882A (es) |
WO (1) | WO2012006205A1 (es) |
ZA (1) | ZA201300154B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011008666A2 (en) * | 2009-07-13 | 2011-01-20 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
RU2013105479A (ru) * | 2010-07-09 | 2014-08-20 | Тереванс, Инк. | Кристаллическая форма соединения 3-феноксиметилпирролидина |
US11013340B2 (en) | 2018-05-23 | 2021-05-25 | L&P Property Management Company | Pocketed spring assembly having dimensionally stabilizing substrate |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
EP1184372B1 (en) * | 2000-08-31 | 2006-04-26 | Pfizer Limited | Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) |
US20070072859A1 (en) * | 2004-03-05 | 2007-03-29 | Eli Lilly And Company | Pharmaceutical compounds |
CN101506164A (zh) * | 2006-08-23 | 2009-08-12 | 辉瑞产品公司 | 哌啶衍生物 |
WO2008153958A2 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
US7888386B2 (en) * | 2008-07-24 | 2011-02-15 | Theravance, Inc. | 3-(phenoxyphenylmethyl)pyrrolidine compounds |
EP2419405A1 (en) * | 2009-04-15 | 2012-02-22 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
WO2011008666A2 (en) * | 2009-07-13 | 2011-01-20 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
RU2013105479A (ru) * | 2010-07-09 | 2014-08-20 | Тереванс, Инк. | Кристаллическая форма соединения 3-феноксиметилпирролидина |
-
2011
- 2011-06-30 RU RU2013105479/04A patent/RU2013105479A/ru not_active Application Discontinuation
- 2011-06-30 AU AU2011276416A patent/AU2011276416B2/en not_active Ceased
- 2011-06-30 CN CN201180033815.4A patent/CN103038211B/zh not_active Expired - Fee Related
- 2011-06-30 JP JP2013518688A patent/JP5823512B2/ja not_active Expired - Fee Related
- 2011-06-30 NZ NZ605490A patent/NZ605490A/en not_active IP Right Cessation
- 2011-06-30 BR BR112013000602A patent/BR112013000602A2/pt not_active IP Right Cessation
- 2011-06-30 CA CA2803090A patent/CA2803090A1/en not_active Abandoned
- 2011-06-30 SG SG2012094348A patent/SG186789A1/en unknown
- 2011-06-30 US US13/173,204 patent/US8163794B2/en not_active Expired - Fee Related
- 2011-06-30 KR KR1020137001583A patent/KR20130041916A/ko not_active Application Discontinuation
- 2011-06-30 WO PCT/US2011/042518 patent/WO2012006205A1/en active Application Filing
- 2011-06-30 EP EP11738521.1A patent/EP2590941A1/en not_active Withdrawn
- 2011-06-30 MX MX2013000334A patent/MX2013000334A/es active IP Right Grant
- 2011-07-07 AR ARP110102429A patent/AR083512A1/es unknown
- 2011-07-08 TW TW100124302A patent/TW201206882A/zh unknown
-
2012
- 2012-03-20 US US13/424,561 patent/US8383669B2/en active Active
- 2012-12-12 IL IL223584A patent/IL223584A0/en unknown
- 2012-12-19 US US13/720,385 patent/US8791151B2/en not_active Expired - Fee Related
-
2013
- 2013-01-07 ZA ZA2013/00154A patent/ZA201300154B/en unknown
- 2013-01-09 CL CL2013000085A patent/CL2013000085A1/es unknown
- 2013-01-09 CO CO13003305A patent/CO6680604A2/es not_active Application Discontinuation
-
2014
- 2014-06-24 US US14/313,422 patent/US9120746B2/en not_active Expired - Fee Related
-
2015
- 2015-03-26 JP JP2015063809A patent/JP2015120752A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BR112013000602A2 (pt) | 2016-07-05 |
IL223584A0 (en) | 2013-03-05 |
CN103038211B (zh) | 2015-04-15 |
CO6680604A2 (es) | 2013-05-31 |
JP2013532170A (ja) | 2013-08-15 |
TW201206882A (en) | 2012-02-16 |
US8791151B2 (en) | 2014-07-29 |
SG186789A1 (en) | 2013-02-28 |
US20120010265A1 (en) | 2012-01-12 |
MX2013000334A (es) | 2013-02-26 |
AU2011276416B2 (en) | 2015-04-02 |
NZ605490A (en) | 2014-10-31 |
WO2012006205A1 (en) | 2012-01-12 |
KR20130041916A (ko) | 2013-04-25 |
US20150080450A1 (en) | 2015-03-19 |
AU2011276416A1 (en) | 2013-02-14 |
US8163794B2 (en) | 2012-04-24 |
EP2590941A1 (en) | 2013-05-15 |
US20120178790A1 (en) | 2012-07-12 |
US20140018407A1 (en) | 2014-01-16 |
US9120746B2 (en) | 2015-09-01 |
JP5823512B2 (ja) | 2015-11-25 |
RU2013105479A (ru) | 2014-08-20 |
US8383669B2 (en) | 2013-02-26 |
ZA201300154B (en) | 2013-09-25 |
JP2015120752A (ja) | 2015-07-02 |
CA2803090A1 (en) | 2012-01-12 |
AR083512A1 (es) | 2013-03-06 |
CN103038211A (zh) | 2013-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
CY1118813T1 (el) | Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων | |
PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
EA201490864A1 (ru) | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов | |
CL2012002733A1 (es) | Compuestos derivados de ácido 1-amino-2-ciclopropiletilborónico, inhibidores de proteasoma; composición farmacéutica; uso en el tratamiento del cáncer; procedimiento de preparacion; compuestos intermediarios. | |
MX2015009591A (es) | Amidas como moduladores de canales de sodio. | |
PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
NZ631144A (en) | Compositions and methods for transmucosal absorption | |
MX366393B (es) | Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol. | |
WO2011093826A3 (en) | Effervescent formulations comprising cefaclor and clavulanic acid as active agents | |
MX363007B (es) | Uso de n-acetil-5-metoxi-triptamina o analogos de la misma para potenciar el mecanismo de implantacion del embrion, y composiciones y medios de cultivo relacionados. | |
PH12015501609A1 (en) | Phenicol antibacterials | |
MX365427B (es) | Composiciones transdermicas de ibuprofeno y metodos de uso de las mismas. | |
ES2397889A1 (es) | PÉPTIDOS MODULADORES DE PGC-1Alfa. | |
EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
MX338554B (es) | Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor. | |
ECSP11011095A (es) | Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3. | |
CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
ECSP13012453A (es) | 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3 | |
EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
CL2012000097A1 (es) | Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros. | |
CL2012002259A1 (es) | Forma cristalina de 4-{(1s,2s)-2-[84-ciclobutilpiperazin-1-il-carbonil]ciclopropil}benzamida; composicion farmacéutica; y su uso para tratar enfermedades tales como esquizofrenia, narcolepsia, somnolencia diurna excesiva, obesidad, trastornos por deficit de atencion con hiperactividad, dolor, entre otras. | |
CL2013000085A1 (es) | Sal cristalina de (s)-3-[(s)-1-(4-clorofenoxi)-2-metilpropil]pirrolidina y acido clorhidrico en una relacion molar 1:1; composicion farmaceutica; proceso de preparacion; y su uso para el tratamiento del dolor, un trastorno depresivo, un trastorno afectivo, obesidad, entre otras. |